Abstract
Exocrine pancreatic cancer is one of the neoplasias with a worse prognosis, with conventional treatments having little impact on disease outcome. Research and genomic high-throughput technology is continuously expanding our knowledge of pancreas cancer biology. Characterization of genetic and epigenetic alterations in pancreatic tumors has allowed a better understanding of the progression model of the disease at the molecular level. The development of new therapeutic approaches with target-oriented agents is been tested in the preclinical and clinical settings. This review updates the current available data on pancreatic cancer molecular biology.
| Original language | English |
|---|---|
| Pages (from-to) | 306-312 |
| Number of pages | 7 |
| Journal | Clinical and Translational Oncology |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2006 |
| Externally published | Yes |
Keywords
- Genetic alterations
- Molecular biology
- New drugs
- Pancreatic cancer